CBT/SSRI
PreclinicalSmall molecule
CBT/SSRI is one of 17 small molecule programs targeting Panic Disorder. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Panic Disorder
#DrugCompanyPhaseTrials
1Brintellix
TakedaApproved
Cymbalta
Jazz PharmaceuticalsApproved
Atarax
PfizerApproved
Paxil
SSebela Pharmaceuticals Development LLC
Approved
Lexapro
AbbVieApproved
Celexa
AbbVieApproved
Xanax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Zoloft
VViatris Specialty LLC
Approved
Klonopin
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Seroquel Xr
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Panic Disorder1 trial
Panic Disorder and Cardiac Risk
Unknown status·—·N/A·NCT00168506·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CBT/SSRI. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- BBaker Heart Research Institute